Caribou Biosciences (CRBU) Total Non-Current Liabilities (2020 - 2022)
Caribou Biosciences (CRBU) posted quarterly Total Non-Current Liabilities of $72.9 million for Q4 2022, up 33.72% year-over-year from $54.5 million in Q4 2021, and down 2.43% quarter-over-quarter from $74.7 million in Q3 2022.
Caribou Biosciences (CRBU) Total Non-Current Liabilities (2020 - 2022) Analysis & Trends
Caribou Biosciences (CRBU) has reported Total Non-Current Liabilities for 3 consecutive years, with $72.9 million the latest figure, recorded in Q4 2022.
- In Q4 2022, Total Non-Current Liabilities rose 33.72% year-over-year to $72.9 million; the TTM figure through Dec 2022 stood at $72.9 million (up 33.72% YoY), while the FY2022 annual figure was $72.9 million, up 33.72% from the prior year.
- Total Non-Current Liabilities fell to $72.9 million in Q4 2022 per CRBU's latest filing, from $74.7 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $74.7 million in Q3 2022 and bottomed at $18.0 million in Q4 2020.
- Historically, Total Non-Current Liabilities has averaged $60.1 million across 3 years, with a median of $65.1 million in 2021.
- Annual changes were most pronounced in 2021 — Total Non-Current Liabilities soared 203.12% — and 2022, when it surged 30.14%.
- Caribou Biosciences' Total Non-Current Liabilities stood at $18.0 million in 2020, then jumped by 203.12% to $54.5 million in 2021, then surged by 33.72% to $72.9 million in 2022.
- Business Quant data shows CRBU's Total Non-Current Liabilities at $72.9 million in Q4 2022, $74.7 million in Q3 2022, and $73.5 million in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 9.32 Bn |
| 10 | Caribou Biosciences | 167.13 Mn | 54.82 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 72.89 Mn |
| Sep 30, 2022 | 74.71 Mn |
| Jun 30, 2022 | 73.48 Mn |
| Mar 31, 2022 | 74.19 Mn |
| Dec 31, 2021 | 54.51 Mn |
| Sep 30, 2021 | 57.41 Mn |
| Jun 30, 2021 | 55.78 Mn |
| Dec 31, 2020 | 17.98 Mn |